Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)

Next Previous
Trial Profile

A Phase III Study of Pembrolizumab (MK-3475) vs. Best Supportive Care as Second-Line Therapy in Subjects With Previously Systemically Treated Advanced Hepatocellular Carcinoma (KEYNOTE-240)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-240
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 04 Jun 2024 Results from Exploratory analyses , assessing Association between beta-catenin (CTNNB1) mutations and clinical outcomes of pembrolizumab in advanced hepatocellular carcinoma , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 13 Sep 2022 Results reporting safety and efficacy data from KEYNOTE-240 after 4.5 years of extended follow-up presented at the 47th European Society for Medical Oncology Congress
  • 13 Apr 2022 Results of prespecified meta-analysis of KEYNOTE-240 and KEYNOTE-394 obtaining a precise estimate of the pembro treatment effect, presented at the 113th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top